U.S. markets closed

Kezar Life Sciences, Inc. (KZR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.92-0.43 (-4.60%)
At close: 4:00PM EDT
8.94 +0.02 (0.22%)
After hours: 05:26PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close9.35
Open9.18
Bid8.58 x 800
Ask9.06 x 900
Day's Range8.66 - 9.27
52 Week Range4.34 - 9.79
Volume338,549
Avg. Volume260,907
Market Cap429.88M
Beta (5Y Monthly)0.41
PE Ratio (TTM)N/A
EPS (TTM)-0.95
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kezar Life Sciences, Inc.
    Analyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • TipRanks

    3 Hot Growth Stocks to Beat the Market Volatility

    Volatility is back on the menu. U.S. stocks began the week deeply in the red as investors grappled with a number of risks, including a possible shift in Federal Reserve guidance this week that could hurt corporate profits. There are also concerns that Evergrande - a major Chinese property developer - could default on its hundreds of billions in debt and trigger a financial crisis beyond China. The key to success in this environment is really the same as in ‘normal’ times. Look for stocks with so

  • Business Wire

    Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., September 02, 2021--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in the following upcoming virtual investor conferences:

  • Business Wire

    Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis

    SOUTH SAN FRANCISCO, Calif., August 23, 2021--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that PRESIDIO, its Phase 2 clinical trial to evaluate the safety and efficacy of KZR-616 for the treatment of polymyositis (PM) and dermatomyositis (DM) completed the target enrollment of 24 subjects.